Get Premium to unlock powerful stock data

Copernicus Capital Management, LLC Buys Pfizer Inc, Thermo Fisher Scientific Inc, Teladoc Health Inc, Sells Vertex Pharmaceuticals Inc, Atara Biotherapeutics Inc, Zentalis Pharmaceuticals Inc

Author's Avatar
insider
Nov 16, 2021
Article's Main Image
Investment company Copernicus Capital Management, LLC (Current Portfolio) buys Pfizer Inc, Thermo Fisher Scientific Inc, Teladoc Health Inc, Biomarin Pharmaceutical Inc, Johnson & Johnson, sells Vertex Pharmaceuticals Inc, Atara Biotherapeutics Inc, Zentalis Pharmaceuticals Inc, TCR2 Therapeutics Inc, Accolade Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Copernicus Capital Management, LLC. As of 2021Q3, Copernicus Capital Management, LLC owns 13 stocks with a total value of $8 million. These are the details of the buys and sells.

For the details of Copernicus Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/copernicus+capital+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Copernicus Capital Management, LLC
  1. Pfizer Inc (PFE) - 30,000 shares, 15.61% of the total portfolio. New Position
  2. Thermo Fisher Scientific Inc (TMO) - 2,000 shares, 13.83% of the total portfolio. New Position
  3. Teladoc Health Inc (TDOC) - 7,000 shares, 10.75% of the total portfolio. New Position
  4. Biomarin Pharmaceutical Inc (BMRN) - 11,000 shares, 10.29% of the total portfolio. New Position
  5. Johnson & Johnson (JNJ) - 5,000 shares, 9.78% of the total portfolio. New Position
New Purchase: Pfizer Inc (PFE)

Copernicus Capital Management, LLC initiated holding in Pfizer Inc. The purchase prices were between $39.25 and $50.42, with an estimated average price of $44.27. The stock is now traded at around $49.135000. The impact to a portfolio due to this purchase was 15.61%. The holding were 30,000 shares as of 2021-09-30.

New Purchase: Thermo Fisher Scientific Inc (TMO)

Copernicus Capital Management, LLC initiated holding in Thermo Fisher Scientific Inc. The purchase prices were between $509.53 and $609.78, with an estimated average price of $548.6. The stock is now traded at around $649.430000. The impact to a portfolio due to this purchase was 13.83%. The holding were 2,000 shares as of 2021-09-30.

New Purchase: Teladoc Health Inc (TDOC)

Copernicus Capital Management, LLC initiated holding in Teladoc Health Inc. The purchase prices were between $125.92 and $164.64, with an estimated average price of $145.86. The stock is now traded at around $134.910000. The impact to a portfolio due to this purchase was 10.75%. The holding were 7,000 shares as of 2021-09-30.

New Purchase: Biomarin Pharmaceutical Inc (BMRN)

Copernicus Capital Management, LLC initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $74.77 and $85.47, with an estimated average price of $79.09. The stock is now traded at around $82.050000. The impact to a portfolio due to this purchase was 10.29%. The holding were 11,000 shares as of 2021-09-30.

New Purchase: Johnson & Johnson (JNJ)

Copernicus Capital Management, LLC initiated holding in Johnson & Johnson. The purchase prices were between $161.5 and $179.47, with an estimated average price of $170.65. The stock is now traded at around $163.010000. The impact to a portfolio due to this purchase was 9.78%. The holding were 5,000 shares as of 2021-09-30.

New Purchase: Allogene Therapeutics Inc (ALLO)

Copernicus Capital Management, LLC initiated holding in Allogene Therapeutics Inc. The purchase prices were between $21.01 and $27.64, with an estimated average price of $23.81. The stock is now traded at around $19.110000. The impact to a portfolio due to this purchase was 4.67%. The holding were 15,000 shares as of 2021-09-30.

Sold Out: Vertex Pharmaceuticals Inc (VRTX)

Copernicus Capital Management, LLC sold out a holding in Vertex Pharmaceuticals Inc. The sale prices were between $181.39 and $202.99, with an estimated average price of $195.37.

Sold Out: Atara Biotherapeutics Inc (ATRA)

Copernicus Capital Management, LLC sold out a holding in Atara Biotherapeutics Inc. The sale prices were between $11.99 and $17.9, with an estimated average price of $14.37.

Sold Out: Zentalis Pharmaceuticals Inc (ZNTL)

Copernicus Capital Management, LLC sold out a holding in Zentalis Pharmaceuticals Inc. The sale prices were between $46.83 and $73.5, with an estimated average price of $57.7.

Sold Out: TCR2 Therapeutics Inc (TCRR)

Copernicus Capital Management, LLC sold out a holding in TCR2 Therapeutics Inc. The sale prices were between $8.44 and $18.35, with an estimated average price of $14.22.

Sold Out: Accolade Inc (ACCD)

Copernicus Capital Management, LLC sold out a holding in Accolade Inc. The sale prices were between $41.3 and $54.56, with an estimated average price of $47.11.

Sold Out: Jazz Pharmaceuticals PLC (JAZZ)

Copernicus Capital Management, LLC sold out a holding in Jazz Pharmaceuticals PLC. The sale prices were between $128.64 and $184.79, with an estimated average price of $151.34.



Here is the complete portfolio of Copernicus Capital Management, LLC. Also check out:

1. Copernicus Capital Management, LLC's Undervalued Stocks
2. Copernicus Capital Management, LLC's Top Growth Companies, and
3. Copernicus Capital Management, LLC's High Yield stocks
4. Stocks that Copernicus Capital Management, LLC keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus